JPRN-UMIN000024697已完成未知
Comparison of inravitreal ranibizumab therapy with and without laser photocoagulation for diabetic macular edema. - Comparison of inravitreal ranibizumab therapy with and without laser photocoagulation for diabetic macular edema.
Tokyo Women's Medical University0 个研究点目标入组 100 人开始时间: 2016年11月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Other ocular disease. Laser photocoagulation within 3 months. Anti-VEGF therapy within 3 months. Focal steroid injection within 3 months. Diabetic retinopthy over 85 ETDRS grades. After any vitrectomy. After cataract surgery. Focal diabetic macular edema.
研究者
相似试验
已完成
不适用
Comparison of intravitreal ranibizumab injection with or without tissue plasminogen activator in the treatment of type 2 choroidal neovascularizationeovascular age-related macular degenerationJPRN-UMIN000017081Department of Ophthalmology and Visual Science Nagoya City University Graduate School of Medical Sciences20
尚未招募
4 期
A clinical trial to compare effect of Injection Ranibizumab 0.25 mg versus Injection Aflibercept 1mg in infants of Retinopathy of Prematurity.CTRI/2023/06/054362Army Hospital Referral and Research
招募中
2 期
A phase II, 12 month, randomized, sham-controlled trial of ranibizumab (Lucentis) combined with grid laser compared with laser alone for the treatment of recalcitrant, diabetic macular oedema.Diabetic Macular OedemaEye - Diseases / disorders of the eyeMetabolic and Endocrine - DiabetesDiabetic RetinopathyACTRN12611000063910ovartis40
进行中（未招募）
不适用
Comparision of Ranibizumab (Lucentis) Monotherapy versus Combination of Ranibizumab (Lucentis) with Photodynamic Therapy (Verteporfin) in Patients with Subfoveal Choroidal Neovascularisation due to Age-Related Macular Degeneration - KAV-RanibizumabEUCTR2006-006760-28-ATudwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie45
进行中（未招募）
1 期
Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD)Subfoveal neovascular age-related macular degenerationMedDRA version: 18.1Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 18.1Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2015-001961-20-ESBioeq GmbH650